Mastek Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rr9apqtntaox0f4je74syvmt.pdf

Key Takeaways


Revenue & Margin Performance

Hiral Chandrana: "some of that might come at margins which are below in the short term. But as long as we are confident that we can drive operational rigor, efficiencies, automation, and making sure that overall profitability is kept at company level, we will go after some of those large deals."

UK Public Sector & Secure Government


US Business & Healthcare Momentum

Hiral Chandrana: "there is a good threshold of USD 100 million that we have crossed and that's now giving us confidence that, hey, we can aim for the next USD 100 million."

Account Strategy & Order Book

Hiral Chandrana: "We have been much more careful in terms of the new logos... we are mostly focused on now clients above USD 1 billion, in many cases USD 2 billion, USD 5 billion, USD 10 billion clients."

NHS Revival & UK Healthcare

Hiral Chandrana: "I wish we had done that earlier, frankly. And now we have a complete plan for NHS revival and growth paths where the team is plotting not just one area, but multiple areas beyond the central agency of NHS."

Geographic & Portfolio Reshaping

Hiral Chandrana: "we have started to exit certain geographies like Malaysia, Singapore, and India business that has resulted in a little bit of attrition spike, but we believe that will stabilize and keep going down in the future quarters."

Guidance & Commitments

CommitmentSpecificsTimeline
Margin rangeOperate between 17-19% EBITDA; combination of Middle East and US margin improvement to bring overall profile to midpoint of that rangeSteady state going forward
US margin improvementMargin profile will continue to improve; more leverage definitely availableOngoing
Headcount growthAs utilization improves and more customers are added, company will look to increase headcountComing quarters
NHS growthNHS accounts will grow, but management remains cautiousFY '25
Secure government growthCentral government and defense will continue to grow at company average rateQ4 and beyond into FY '25
Attrition stabilizationAttrition spike from geographic exits expected to stabilize and declineFuture quarters
Large deal participationWill start competing in larger deals, accepting short-term margin dilution while maintaining overall company profitabilityOngoing

Key Metrics

MetricQ3 FY24
Revenue₹784 cr, up 2.4% QoQ and 19.1% YoY
Revenue growth (USD terms)17.4% YoY
Constant currency revenue growth2.7% QoQ and 13.4% YoY
Organic constant currency revenue growth0.7% QoQ
Operating EBITDA margin17.0%, up 90 bps QoQ
Profit after tax₹77.7 cr, up 19% QoQ and 15.8% YoY
12-month order backlog$248 million, up 11% QoQ and 21% YoY
Order book backlog growth21.2% YoY
Utilization (excluding leave)85.4%, up 130 bps QoQ
Closing headcount5,518, net reduction of 80
New customers added27 during the quarter
Gross cash₹404 cr as of December 31, 2023
Borrowing₹464 cr at end of December
Net debt₹60 cr at end of December 31
Dividend declared140%, ₹7 per share